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Background: State-of-the-art care involving the utilisation of multiple health care interventions is the basis for an
optimal long-term clinical prognosis for HIV-patients. We evaluated health care for HIV patients based on four key
indicators.
Methods: Four indicators of health care were assessed: Compliance with current guidelines on initiation of: 1)
combination antiretroviral therapy (cART); 2) chemoprophylaxis; 3) frequency of laboratory monitoring; and 4)
virological response to cART (proportion of patients with HIV-RNA < 500copies/ml for >90% of time on cART).
Results: 7097 EuroSIDA patients were included from Northern (n = 923), Southern (n = 1059), West Central (n = 1290)
East Central (n = 1366), Eastern (n = 1964) Europe, and Argentina (n = 495). Patients in Eastern Europe with a
CD4 < 200cells/mm3 were less likely to initiate cART and Pneumocystis jiroveci-chemoprophylaxis compared to patients
from all other regions, and less frequently had a laboratory assessment of their disease status. The proportion of
patients with virological response was highest in Northern, 89% vs. 84%, 78%, 78%, 61%, 55% in West Central, Southern,
East Central Europe, Argentina and Eastern Europe, respectively (p < 0.0001). Compared to Northern, patients from
other regions had significantly lower odds of virological response; the difference was most pronounced for Eastern
Europe and Argentina (adjusted OR 0.16 [95%CI 0.11-0.23, p < 0.0001]; 0.20[0.14-0.28, p < 0.0001] respectively).
Conclusions: This assessment of HIV health care utilization revealed pronounced regional differences in adherence to
guidelines and can help to identify gaps and direct target interventions. It may serve as a tool for the assessment and
benchmarking of the clinical management of HIV patients in any setting worldwide.
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in EuropeBackground
Standards of care for HIV patients are established by na-
tional and international guidelines, but vary across the
world depending on the economic situation in a particu-
lar country, health system infrastructures and the preva-
lence of HIV [1-4]. State-of-the-art care of HIV patients
requires the utilisation of multiple health care interven-
tions, not only limited to laboratory and clinical* Correspondence: dpo@cphiv.dk
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distribution, and reproduction in any mediumprocedures for disease monitoring, but also involving
health system multisectoral interventions such as the
procurement of antiretroviral drugs and laboratory
equipment. In many countries, access to combination
antiretroviral therapy (cART) is limited as are choice of
drugs and treatment options, and monitoring of treat-
ment efficacy with CD4-cell count and HIV-RNA mea-
surements is often not possible [5].
Proper utilisation of health care interventions depends
on several factors including health system financing and
prioritisation, qualification and knowledge level of physi-
cians, as well as the patients’ ability to access thentral Ltd. This is an Open Access article distributed under the terms of the
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Deficits in provided care may have important implica-
tions for the health of the individual HIV patient as well
as for public health [6]. Several attempts have been
made to develop HIV care quality measures which are
typically limited to one country or a single clinic [7,8].
The World Health Organization (WHO) has also devel-
oped a set of indicators for monitoring the health sys-
tems response to HIV/AIDS [9], which are mainly
focused on health systems per se without the capability
to monitor clinical management of patients (i.e. their im-
munological and virological status). Currently, there is a
lack of knowledge about health care utilization on a
multinational level within resource-rich and -poor set-
tings, in particular health care adherence to the clinical
guidelines on management of HIV infection. The devel-
opment of uniform measures for HIV care quality would
allow cross-regional comparison and the identification
of a benchmark for HIV care.
The EuroSIDA study represents a unique opportunity
for assessing the clinical management of HIV infection
on an individual level as well as enabling comparison
across different regions in Europe and Argentina. Our
objectives were to evaluate the performance of four
health care indicators (HCI), all based on current HIV
treatment guidelines [1-4], and compare their utilisation
across regions of Europe and Argentina in order to sug-
gest a clinical benchmark for HIV health care.
Methods
EuroSIDA study
EuroSIDA is a prospective observational cohort study of
16,597 HIV patients from 103 clinics in 35 countriesHCI 1, when to start cART
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or start cART during follow-up (N=1,273)
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enrolled d
2001 - 2
(cohorts 
16.597 HIV-infected pa
as per Janua
Figure 1 Inclusion criteria for EuroSIDA patients in the analysis of fou
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This analysis is based on patients recruited into the
study after 2001, when EuroSIDA expanded its network to
Eastern Europe. Information is collected on a standar-
dized, adjustable data collection form at enrolment and
every six months thereafter (www.eurosida.org). Informa-
tion collected includes all CD4-cell counts and HIV-RNA
measured since the last follow-up, dates of starting and
stopping each antiretroviral drug as well as drugs used for
treatment and chemoprophylaxis against opportunistic
infections. Dates of diagnosis of all AIDS-defining illnesses
are also recorded using the 1993 clinical definition of
AIDS from the US Centers for Disease Control [12]. A
comprehensive quality assurance programme has been
established to ensure correct patient selection and to ver-
ify that accurate data are supplied. The study was
approved by the Ethics Committees of participating clinics
(N = 103), as per local and national regulations. All
patients’ data were obtained from patients’ medical
records or via database exchange using HICDEP format
(www.hicdep.org). Patients had to sign Informed Consent
where it was requested by local regulations.
Statistical methods
Patients eligible for this analysis were those enrolled in
EuroSIDA from 2001 onwards with at least one follow-
up visit after baseline. For regional analysis of HCI, six
regions were established according to the country of
residence of the patient:
 Southern Europe (SE): Greece, Israel, Italy, Portugal,
Spain;HCI 3, frequency of laboratory monitoring
2,511 patients in the off cART group
5,859 patients in the on cART group
HCI 4, virological responce
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at baseline and subsequently have not started cART. If patients
T group included patients who were on cART at baseline or started
). HCI 4: patients who were on cART for at least 4 consecutive months
irst 4 months after each start/change of cART were excluded to ensure
ded in the measure of HCI [14]. Follow-up was censored if a patient
the next available HIV-RNA measurement (5277).
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France, South Germany, Luxembourg, Switzerland;
 North Europe (NE): Denmark, Finland, North
Germany, Ireland, the Netherlands, Norway,
Sweden, the United Kingdom;
 East Central Europe (ECE): Bulgaria, Croatia, the
Czech Republic, Hungary, Poland, Romania, Serbia
and Slovakia;
 Eastern Europe (EE): Belarus, Estonia, Latvia,
Lithuania, the Russian Federation and the Ukraine;
 Argentina (AR)
Health care provided to HIV patients in different
regions was assessed using four HCI, as presented below,
and chosen according to the main recommendations of
international guidelines on the management of HIV
patients [1-4]. The selection of patients for analysis of
each HCI is explained in Figure 1.
1. Compliance with current guidelines on when to start
cART, based on CD4-cell count or presence of AIDS
diagnosis [1;2;3]
2. Compliance with current guidelines on prophylaxis
of opportunistic infections, i.e. initiating of
Pneumocystis jiroveci pneumonia (PCP)
chemoprophylaxis at CD4-cell count <200 cells/mm3
and no prior diagnosis of PCP [13]
3. Laboratory evaluation of HIV-disease status: median
number of CD4-cell count and HIV-RNA
measurements performed per patient per follow-up
year, stratified by whether patients were off or on
cART
4. Virologic response to cART, assessed by the
proportion of patients spending more than 90% of
the follow-up time on cART with suppressed
HIV-RNA (<500 copies/ml) [14].
cART was defined as at least two nucleos(t)ide reverse
transcriptase inhibitors (NRTI) plus either one non-
nucleoside reverse transcriptase inhibitor (NNRTI), pro-
tease inhibitor (PI)/ritonavir boosted (b) PI or abacavir.
Baseline was defined as the date of enrolment into the
EuroSIDA study. Descriptive statistics were used to
compare patients’ baseline characteristics across the six
regions. Baseline CD4-cell counts and HIV-RNA mea-
surements were assessed using measurements closest to,
and no longer than, six months prior to baseline.
Logistic regression was used to identify factors asso-
ciated with suppressed HIV-RNA for more than 90% of
the follow-up time on cART. Follow-up after starting
cART was limited to the actual time on cART, excluding
treatment interruptions and periods of non-cART use.
The first 4 months after each start or change of cARTwere excluded from the analysis to ensure that periods
when viral suppression would not be expected were not
included in the measure of HCI [14]. Follow-up was
censored if a patient had not had a HIV-RNA measure-
ment for >6 months and continued from the next avail-
able HIV-RNA measurement. The following variables
were considered in univariable analyses: region of resi-
dence, gender, age, race, risk factors for HIV exposure,
type of cART regimen, treatment naïve at starting cART,
hepatitis B/C (HBV/HCV) status, date of starting cART,
baseline and nadir CD4-cell count, baseline and maximal
HIV-RNA. Factors that were significant in the univari-
able model (p < 0.1) were then incorporated in the mul-
tivariable model. Missing values were included in the
analysis as a separate category for the categorical vari-
ables; for the continuous variables the inclusion criteria
for the time on cART with a suppressed HIV-RNA ana-
lysis was having CD4-cell count and HIV-RNA data
available.
A sensitivity analysis was performed on a subset of
patients on cART with HIV-RNA measurements per-
formed using assays with a 50 copies/ml limit of
quantification.
Follow-up until a median last visit date of April 2011
(IQR February 2010-September 2011) was included in
the present analysis, and all analyses were performed
using SAS (Statistical analysis software, Cary, NC, USA)
version 9.1.
Results
A total of 7366 patients were recruited to EuroSIDA after
2001 and of those 7097 had at least one follow-up visit
and were included in this analysis (Figure 1). Patients’
characteristics are shown in Table 1. Patients from EE dif-
fered considerably from patients in other regions. They
were younger, with a higher proportion of females; half of
them were infected with HIV by injecting drug use (IDU)
and were coinfected with HCV. 61% of patients in EE
were cART-naïve when recruited to the study. A higher
proportion of patients from AR than the other regions
were infected with HIV by heterosexual contact and more
had been diagnosed with AIDS at baseline.
HCI 1 Compliance with current guidelines on when to
start cART
Figure 2 shows changes over time in the proportions of
patients starting cART within different strata of CD4-
cell counts according to the region of residence. Of all
patients starting cART (N = 5859, Figure 1), the propor-
tion doing so at a CD4-cell count <200 cells/mm3 or an
AIDS diagnosis decreased by 20% in SE (from 43% to
23%), 22% in WCE (from 44% to 22%), 32% in NE (from
49% to 17%),19% in ECE (from 52% to 31%) and 9% in
AR (from 58% to 49%) from ≤ 2004 till ≥ 2007. In EE,
Table 1 Baseline characteristics of the EuroSIDA patients, included in the study after January 1st, 2001 and according
to the region of residence
SE WCE NE ECE EE AR p
1059 1290 923 1366 1964 495
N (% of total)
Gender Male 799 (75.5) 992 (76.9) 702 (76.1) 968 (70.9) 1103 (56.2) 307 (62.0) <.0001
Ethnic origin White 952 (90.0) 911 (76.7) 749 (81.9) 1358 (99.6) 1958 (99.9) 488 (98.6) <.0001
Exposure
Group
Homosexual 7426 (40.2) 566 (43.9) 473 (51.3) 508 (37.2) 149 (7.6) 126 (25.5) <.0001
IDU 188 (17.8) 128 (9.9) 86 (9.9) 345 (25.3) 923 (47.0) 62 (12.5)
Heterosexual 359 (33.9) 404 (31.3) 290 (31.4) 410 (30.0) 791 (40.3) 291 (58.8)
Treatment
History
Naïve 253 (23.9) 183 (14.2) 145 (15.7) 259 (19.0) 1200 (61.1) 82 (16.6) <.0001
cART 763 (72.0) 1035 (80.2) 744 (80.6) 1016 (74.4) 632 (32.2) 396 (80.0)
Hepatitis
B surface
antigen status
positive 45 (4.3) 58 (4.5) 35 (3.8) 60 (4.4) 107 (5.5) 26 (5.3) .003
negative 827 (78.1) 996 (77.2) 742 (80.4) 1115 (81.6) 1562 (79.5) 357 (72.1)
unknown 187 (17.7) 236 (18.3) 146 (15.8) 191 (14.0) 295 (15.0) 112 (22.6)
Hepatitis C
antibody
status
positive 174 (16.4) 155 (12.0) 81 (8.8) 352 (25.8) 950 (48.4) 91 (18.4) <.0001
negative 688 (65.0) 874 (67.8) 662 (71.6) 831 (60.8) 666 (33.9) 295 (59.6)
unknown 197 (18.6) 261 (20.2) 180 (19.5) 183 (13.4) 348 (17.7) 109 (22.0)
Previous AIDS
diagnosis
yes 180 (17.0) 352 (27.3) 187 (20.3) 312 (19.9) 391 (19.9) 101 (32.5) <.0001
Median (IQR)
Age 39 (33–46) 42 (36–49) 42 (36–50) 35 (29–42) 30 (26–36) 36 (31–43) <.0001
CD4-cell count/mm3 1 434 (293–636) 447 (305–628) 432 (310–610) 369 (245–524) 415 (267–575) 346 (199–518) <.0001
HIV-RNA (log10) copies/ml
2 2.05 (1.70-4.08) 1.70 (1.70-3.33) 1.70 (1.60-3.28) 2.33 (1.70-3.79) 3.48 (2.60-4.58) 2.19 (1.70-4.00) <.0001
Baseline date 1/06 (11/03-6/06) 1/06 (11/03-8/06) 1/06 (11/03-6/08) 11/05 (1/02-6/08) 1/06 (2/04-6/08) 2/06 (1/03-6/06) <.0001
Baseline date defined as the date of enrolment into the EuroSIDA study.
IDU, injection drug user; cART, combination antiretroviral therapy; HIV-RNA, viral load;
SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain; WCE, West Central Europe: Austria, Belgium, France, South Germany, Luxembourg, Switzerland; NE,
Northern Europe: Denmark, Finland, North Germany, Ireland, the Netherlands, Norway, Sweden, the United Kingdom; ECE, East Central Europe: Bulgaria, Croatia,
the Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine;
AR, Argentina.
1 N (%) CD4-cell count measurements were missing for 33 (3.1), 36 (2.8), 26 (2.8), 67 (4.69), 418(21.3) and 104 (21.0) in SE, WCE, NE, ECE, EE and AR respectively.
2 N (%) HIV-RNA measurements were missing for: 52 (4.9), 49 (3.8), 21 (2.3), 252 (18.5), 1289 (65.6) and 132 (26.7) in SE, WCE, NE, ECE, EE and AR respectively.
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CD4-cell count <200 cells/mm3 or at AIDS diagnosis in
2007 or later compared with ≤2004 (48% vs. 44%).
Among patients starting cART at CD4-cell count <200
cells/mm3, median peak CD4-cell count prior to cART
initiation was highest in EE [188 cells/mm3 (IQR 106–
460 cells/mm3)], whereas it was similar in the other
regions [from 92 cells/mm3 (40–170 cells/mm3) in AR
till 120 cells/mm3 (50–194 cells/mm3) in WCE)].
In 2007, HIV treatment guidelines were modified to
recommend the initiation of cART at a CD4-cell count
≤350 cells/mm3 [1-3]. Subsequently, the proportion of
patients starting cART at a CD4-cell count of 200–350
cells/mm3 increased compared to ≤2004 in SE from 22%
to 44%, in WCE from 22% to 45%, in NE from 25% to
54%, in ECE from 26% to 40%, in EE from 22% to 39%
and in AR from 14 to 43% (Figure 2).A total of 1583 patients had been diagnosed with an
AIDS defining disease before the baseline. Of those, 216
(14%) did not start cART. The proportion of AIDS-
patients who did not start cART was highest in EE,
(38%) compared to 4%, 6%, 6%, 8% and 2% from SE,
WCE, NE, ECE and AR respectively (p < 0.0001).
HCI 2 Compliance with current guidelines on prophylaxis
of opportunistic infections
6797 patients were included in this analysis (Figure 1).
The proportion of CD4-cell measurements <200 cells/
mm3 where patients were receiving PCP prophylaxis
was generally highest in Argentina in all three time
periods (93%, 87% and 83% in < 2004, 2005–2006
and >2007, respectively) and lowest in Eastern Europe
(57%, 41%, 38% in < 2004, 2005–2006 and >2007, re-
spectively) (p < 0.0001) (Figure 3).
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Figure 2 Proportion of EuroSIDA patients starting cART at various CD4-cell strata and presence of AIDS diagnosis according to the
region of residence and calendar year. SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain; WCE, West Central Europe: Austria,
Belgium, France, South Germany, Luxembourg, Switzerland; NE, Northern Europe: Denmark, Finland, North Germany, Ireland, the Netherlands,
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Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine.
Podlekareva et al. BMC Infectious Diseases 2012, 12:229 Page 5 of 10
http://www.biomedcentral.com/1471-2334/12/229HCI 3 Laboratory evaluation of HIV disease status
There were 2511 and 5859 patients included in the off
and on cART analyses, respectively (Figure 1). In general,
patients in EE and AR had less frequent CD4-cell count
and HIV-RNA measurements per patient per year of
follow-up compared with the other regions (Figure 4).
There was a median of 0.0 HIV-RNA measurements per
patient per year of follow-up in EE (IQR 0.0-0.8) and 0.9
in AR (IQR 0.2-1.2) compared to 1.7 (1.0-2.2) in ECE,
2.7(1.9-3.4) in NE, 3.0 (2.1-4.0) in WCE and 2.4 (1.7-3.3)
in SE in the off cART group, p < 0.0001. Even though
patients in EE and AR who were on cART had their
HIV-RNA measured slightly more often [1.3 (0.7-1.9)
and 1.3 (0.8-1.8), respectively], it was still significantly
less frequent compared to the other regions, p < 0.0001.
Differences in the number of CD4-cell count measure-
ments followed the same pattern (Figure 4).
HCI 4 Virologic response to cART
There were 5277 patients who were on cART for more
than 4 consecutive months with CD4-cell count and
HIV-RNA measurements available (Figure 1).
The proportion of patients spending more than 90% of
the follow-up time on cART with HIV-RNA < 500 cop-
ies/ml was also highest in NE, 89% compared with 84%
in WCE, 78% in SE and 78% ECE and only 61% and 55%
in AR and EE, p < 0.0001.
Regional differences in the response to cART
remained after adjustment for other factors that poten-
tially might influence the proportion of time withsuppressed HIV-RNA. Compared with NE, the odds of a
suppressed HIV-RNA during at least 90% of the time on
cART were approximately 5-6–fold lower in EE and AR,
and 2-fold lower in the ECE and SE (Figure 5). Other
factors significantly associated with the odds of having
suppressed HIV-RNA at least 90% of the time on cART
were being ART naïve at initiation of cART vs. ART-
experienced [1.43(1.19-1.71), p < 0.0001], being older
[1.16 (1.07-1.25) per additional 10 years, p = 0.0004],
starting cART more recently [1.13 (1.11-1.16) per year, p
< 0.0001] and being infected via homosexual contact vs.
IDU [1.49 (1.13-1.96), p = 0.004]. Patients with a higher
HIV-RNA at starting cART [0.51 (0.49-0.54) per log10
higher, p < 0.0001] and those who initiated (un)boosted
PI- or Abacavir- vs. NNRTI-based regimens [0.67 (0.53-
0.84) p = 0.03, and 0.66 (0.439-0.79) p = 0.001, respect-
ively] had significantly lower odds of having suppressed
HIV-RNA at least 90% of the time on cART.
The proportion of patients with HIV-RNA results
available from assays with a detection level of 50copies/
ml varied across regions: 91%, 90%, 80%, 68%, 62% and
27% in AR, NE, WCE, SE, EC and EE, respectively.
However, results remained similar when sensitivity ana-
lysis of HCI 4 was performed among these patients (N =
3504) (data not shown).
Discussion
This is the first study that employs a concise set of indi-
cators, based on current treatment guidelines, to assess
and compare the delivery of health care in a large and
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Figure 3 Proportion of CD4-cell measurements < 200 cells/mm3 where patients were receiving prophylaxis for Pneumocystis jiroveci
pneumonia (PCP) and had not had PCP diagnosis. SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain; WCE, West Central Europe: Austria,
Belgium, France, South Germany, Luxembourg, Switzerland; NE, Northern Europe: Denmark, Finland, North Germany, Ireland, the Netherlands,
Norway, Sweden, the United Kingdom; ECE, East Central Europe: Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania, Serbia and
Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine; AR, Argentina. cART, combination
antiretroviral therapy.
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http://www.biomedcentral.com/1471-2334/12/229heterogeneous population of HIV patients across coun-
tries with highly varying levels of resources. By testing
this new set of HCI, the study addresses an intriguing
question of quality of HIV care on a regional level rather
than the evaluation of clinical status of an individual pa-
tient. Further, this set of HCI could be adjusted and used
to evaluate the efficacy of treatment programmes for
HIV-positive people elsewhere. The evaluation of health
systems performance represents an important yet oftenFigure 4 Frequency of CD4-cell count and HIV-RNA measurements am
EuroSIDA study. SE, Southern Europe: Greece, Israel, Italy, Portugal, Spain;
Luxembourg, Switzerland; NE, Northern Europe: Denmark, Finland, North G
Kingdom; ECE, East Central Europe: Bulgaria, Croatia, the Czech Republic, H
Belarus, Estonia, Latvia, Lithuania, the Russian Federation and the Ukraine; A
viral load.overlooked instrument for improving the management of
HIV infection. The main focus of the current HCIs is
clinical management of HIV patients, rather than clinical
outcomes, recently published [15]. The results of this
previous study demonstrated an increased mortality in
EE, particularly from AIDS related events, which is con-
sistent with our findings herein of poorer HCI, particu-
larly proportion of time virologically suppressed, in EE.
More specifically, a data-driven identification of the bestong patients not receiving cART and those receiving cART in the
WCE, West Central Europe: Austria, Belgium, France, South Germany,
ermany, Ireland, the Netherlands, Norway, Sweden, the United
ungary, Poland, Romania, Serbia and Slovakia; EE, Eastern Europe:
R, Argentina. cART, combination antiretroviral therapy; HIV-RNA,
Figure 5 Odds Ratio (OR) of having suppressed HIV-RNA
(<500 copies/ml) during more than 90% of time spent on cART.
Multivariable model was also adjusted for: gender, age, race, risk
factor for HIV acquisition, hepatitis B/C status, type of cART regimen,
being ART naïve at initiation of cART, year of cART initiation, baseline
CD4-cell count and HIV-RNA. SE, Southern Europe: Greece, Israel,
Italy, Portugal, Spain; WCE, West Central Europe: Austria, Belgium,
France, South Germany, Luxembourg, Switzerland; NE, Northern
Europe: Denmark, Finland, North Germany, Ireland, the Netherlands,
Norway, Sweden, the United Kingdom; ECE, East Central Europe:
Bulgaria, Croatia, the Czech Republic, Hungary, Poland, Romania,
Serbia and Slovakia; EE, Eastern Europe: Belarus, Estonia, Latvia,
Lithuania, the Russian Federation and the Ukraine; AR, Argentina.
cART, combination antiretroviral therapy; HIV-RNA, viral load.
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clinical benchmark for HIV care which, in turn, enables
the detection of gaps and facilitates continuous quality
improvement of the management of HIV infection.
The assessment of health care quality in general is an
essential component of disease management. A bench-
mark should represent a clinically realistic level of excel-
lence and at the same time exceed mean performance
[16]. To evaluate the utilisation of HIV care we chose
specific clinical process-of-care indicators measuring ad-
herence to existing guidelines (HCIs 1–3), as well as
quality outcome measures, i.e. the ability to achieve the
best clinical response after the initiation of cART (HCI
4). We aimed to identify a set of simply measurable
HCI, which could be easily implemented in any setting.
Although current analysis documents substantial dif-
ferences in the utilisation of HIV care across Europe and
Argentina, underlying reasons for these differences
should be a subject for further investigation. Whereas
there were only few and generally minor differences be-
tween NE, WCE, and SE in most HCIs, EE, AR and to
some extent ECE differed significantly from the rest of
the regions. In terms of time of cART initiation, a signifi-
cantly higher proportion of patients in ECE, EE and ARstarted cART at a CD4-cell count <200 cells/mm3 or after
an AIDS diagnosis, even in recent years despite changes
to guidelines [1-3]. Nevertheless, it is reassuring to see a
slight increase over time in the proportion of patients
starting cART at higher CD4-cell counts in EE. This is
consistent with the fact that access to cART has substan-
tially increased in this region after 2006 [5]. Late cART
initiation could also to some extent be explained by late
presentation. In our study most patients in EE starting
cART at low CD4-cell count are known HIV-infected,
but followed without cART, whereas patients in other
regions to a larger extent are late presenters (data not
shown). This likely reflects the inclusion criteria for the
study. Patients are required to have a pre-booked, out-
patient appointment and hence late presenters, who are
more likely to die or be admitted to hospital, will not be
recruited to the study until they are under routine fol-
low-up.
The use of PCP-chemoprophylaxis was fairly stable
over the years in SE, WCE, NE and ECE. Argentina is
remarkable by the highest use of PCP-chemoprophylaxis
which, for example, could be explained by lower access
to cART in the country in the earlier years (<2004), the
low cost of co-trimoxazole and a high proportion of late
presenters [17]. EE is considered to have a suboptimal
access to cART and a high proportion of AIDS patients
[5]; however, the level of PCP-chemoprophylaxis was ra-
ther low in this region, despite the fact that this is a very
cheap and accessible method to prevent the disease.
Substantial differences in the frequency of laboratory
monitoring for HIV-disease status were observed across
the regions. Current guidelines recommend clinical and
laboratory evaluation of HIV-disease status at least every
half year before initiation of cART and on a 6–12 month
basis in clinically stable patients on cART with suppressed
HIV-RNA [1,3]. Adequate monitoring of untreated
patients is important in terms of the timely initiation of
cARTand the prevention of AIDS and, ultimately, death.
When compared to NE, patients treated with cART in all
other regions, except WCE, had significantly lower odds of
having suppressed plasma HIV-RNA levels for sustained
periods of time. This was particularly true for EE and AR.
The observed regional differences were over and above
what could be explained by differences in patient character-
istics and other factors we could adjust for. There might be
some factors, such as socio-economic and infrastructure
aspects, which play a role and for which we yet do not have
data [18]. The majority of patients from EE acquired HIV
by IDU. This population group is usually younger, more
mobile, less integrated into society and less likely to address
health care [19,20]. The domination in mode of HIV trans-
mission of the IDU population and the likely higher level of
active IDU among HIV-positive patients in EE might par-
tially explain the inferior outcome in this region [18,20].
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a HIV risk factor showed consistent results (data not
shown).
The main goal of cART is to restore the immune sys-
tem through the maximal suppression of viral replication
and thereby minimise the risk of AIDS developing and
death [3]. Regional comparisons of clinical outcomes
have recently been published [15]. Instead, the cut-off of
90% of time on cART spent with suppressed HIV-RNA
was chosen as a benchmark criteria based on a recent
analysis of significantly higher rates of virological failure
in patients spending less than 90% of time on cART with
suppressed HIV-RNA [14]. While EuroSIDA does not
have good data on adherence, likely an important com-
ponent of any HCI, spending >90% of the time of cART
virologically suppressed is probably a marker of good ad-
herence, as those most adherent to cART are most likely
to continually suppress viremia [14].
Limitations of the current analysis should be noted.
Further research is needed to investigate the underlying
reasons for the identified gaps in HIV care. Late cART
initiation, not using PCP prophylaxis in patients with
CD4-cell count <200 cells/mm3 or not measuring CD4-
cell count and HIV-RNA can be equally related to the
specifics of health care infrastructure as well as to the
patients’ behaviour. Addressing the issues above will help
to plan targeted interventions and quality improvement
programmes: whether it should be health care system-,
provider- or patient- oriented. Information on countries’
laws regarding HIV-testing might help to better under-
stand the impact of opt-out HIV-testing on late presenta-
tion of HIV-infection. EuroSIDA is currently collecting
new data and investigating the underlying reasons for dif-
ferences in HCIs. A health care questionnaire to address
site-specific issues within health care utilisation is cur-
rently under development. The main HCI we focused on
was the virologic response to cART, and HIV-RNA was
measured less frequently in EE compared to the other
regions of Europe. Therefore, we may have overestimated
the proportion of time virologically suppressed in EE,
however this fact was taken into account by censoring
the follow-up if there were no HIV-RNA measurement
for >6 months. Finally, EuroSIDA includes predomin-
antly major HIV clinics, and the cohort might not be rep-
resentative for the entire HIV-positive population in
Europe, and especially so in EE. Hence the real life situ-
ation in terms of HIV health care in EE is likely even
worse than presented here.
Comparative analysis of health care utilization and
identification of benchmarks and gaps should help to
better address the problem of managing HIV infection
showing a path towards improvement. Lower-income
regions would not necessarily soon reach the same level
of health care as in high-income regions, but it isimportant to continually seek improvement. With the
current paper we aim to focus public health attention on
the HIV care situation in Eastern Europe, prompting fur-
ther investigations and interventions as appropriate
Conclusion
The criteria we have applied in this evaluation of health care
utilisation for HIV patients were based on current HIV
treatment guidelines and may serve as a tool for bench-
marking the clinical management of HIV infection in Eur-
ope and elsewhere. These criteria may further be adjusted
according to the local setting and, for example, include
aspects of hepatitis and/or tuberculosis coinfection. By com-
parison of HIV care in different regions, the study suggests a
data-driven benchmark for HIV care based on the results
obtained from the region with the best performance. At the
same time, the study emphasizes areas for improvement
within those regions. Further research is needed to investi-
gate and better comprehend the underlying reasons for the
gaps identified. This study also highlights an important pub-
lic health message by documenting substantial differences in
health care utilisation across regions, and urgent measures
should be taken in order to improve access, uptake and re-
sponse to cART, particularly in Eastern Europe, in line with
the global commitment to universal access to prevention,
treatment and care.
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